Person:
Jacobsen, Eric

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Jacobsen

First Name

Eric

Name

Jacobsen, Eric

Filters

20181

Settings

Author's Publications: search.filters.isAuthorOfPublication.92f77d04-25e7-43c8-91de-5c78de50d6d5

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
    (Nature Publishing Group UK, 2018) Ng, Samuel Y.; Yoshida, Noriaki; Christie, Amanda L.; Ghandi, Mahmoud; Dharia, Neekesh; Dempster, Joshua; Murakami, Mark; Shigemori, Kay; Morrow, Sara N.; Van Scoyk, Alexandria; Cordero, Nicolas A.; Stevenson, Kristen E.; Puligandla, Maneka; Haas, Brian; Lo, Christopher; Meyers, Robin; Gao, Galen; Cherniack, Andrew; Louissaint, Abner; Nardi, Valentina; Thorner, Aaron R.; Long, Henry; Qiu, Xintao; Morgan, Elizabeth; Dorfman, David; Fiore, Danilo; Jang, Julie; Epstein, Alan L.; Dogan, Ahmet; Zhang, Yanming; Horwitz, Steven M.; Jacobsen, Eric; Santiago, Solimar; Ren, Jian-Guo; Guerlavais, Vincent; Annis, D. Allen; Aivado, Manuel; Saleh, Mansoor N.; Mehta, Amitkumar; Tsherniak, Aviad; Root, David; Vazquez, Francisca; Hahn, William; Inghirami, Giorgio; Aster, Jon; Weinstock, David; Koch, Raphael
    T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are few preclinical models of TCLs, which has hampered the development of effective therapeutics. Here we establish and characterize preclinical models of TCL. We identify multiple vulnerabilities that are targetable with currently available agents (e.g., inhibitors of JAK2 or IKZF1) and demonstrate proof-of-principle for biomarker-driven therapies using patient-derived xenografts (PDXs). We show that MDM2 and MDMX are targetable vulnerabilities within TP53-wild-type TCLs. ALRN-6924, a stapled peptide that blocks interactions between p53 and both MDM2 and MDMX has potent in vitro activity and superior in vivo activity across 8 different PDX models compared to the standard-of-care agent romidepsin. ALRN-6924 induced a complete remission in a patient with TP53-wild-type angioimmunoblastic T-cell lymphoma, demonstrating the potential for rapid translation of discoveries from subtype-specific preclinical models.